Korro Bio CEO: KRRO-121 Expected Regulatory Filing in H2 2026
"The first quarter marked significant scientific progress for Korro as we continued to advance our OPERA platform and build a pipeline of differentiated RNA editing medicines," commented Ram Aiyar, Chief Executive Officer and President of Korro Bio. "Our lead program, KRRO-121, remains on track for its regulatory filing in the second half of 2026, bringing us closer to delivering a potential first-in-class treatment for patients suffering from hyperammonemia in urea cycle disorders and hepatic encephalopathy. At the same time, our GalNAc-conjugated program for alpha-1 antitrypsin deficiency achieved greater than 90% in vivo RNA editing, a result that reinforces the broad therapeutic potential of the OPERA platform and the first demonstration that close to 100% of RNA can be edited with an oligonucleotide. We are well capitalized following our oversubscribed private placement, which provides us with the resources to reach meaningful clinical milestones across multiple programs. On behalf of the entire Korro team, I wish to extend gratitude to all Korro stakeholders for their belief in the potential of our novel RNA editing platform to transform the treatment of debilitating diseases."
Trade with 70% Backtested Accuracy
Analyst Views on KRRO
About KRRO
About the author
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
